J Korean Med Assoc.  2008 Jun;51(6):524-529. 10.5124/jkma.2008.51.6.524.

End-of-life Decision in Korea

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of Medicine, Korea. heo1013@snu.ac.kr

Abstract

There are more than 65,000 cancer deaths per year in Korea. To what extent should we continue aggressive treatment in terminal patients? In the course of clinical care of a critically ill patient it may become clear that the patient is inevitably dying, the goal of medical treatment should not be to prolong the dying process without benefit to the patient or to others. Further intervention which will do no more than prolong the active dying process is often described as "futile." Even though hospice is widely accepted in Korea, there is still controversy about withholding or withdrawing life-sustaining treatment. Conflicts between the parties may interrupt satisfactory decision-making and adversely affect patient care, family satisfaction, and physicianclinical team functioning. When further intervention to prolong the life of a patient becomes futile, physicians have an obligation to shift the intent of care toward comfort and closure. However, there are necessary value judgments involved in coming to the assessment of futility. In this context, Korean society needs consensus agreement on futility issue, based on our own social values.

Keyword

Futility; Life-sustaining treatment; Terminal patient

MeSH Terms

Consensus
Critical Illness
Hospices
Humans
Judgment
Korea
Medical Futility
Patient Care

Cited by  3 articles

Patient Autonomy and Advance Directives in Korea
Dae Seog Heo
J Korean Med Assoc. 2009;52(9):865-870.    doi: 10.5124/jkma.2009.52.9.865.

Text Network Analysis of Newspaper Articles on Life-sustaining Treatments
Eun-Jun Park, Dae Woong Ahn, Chan Sook Park
J Korean Acad Community Health Nurs. 2018;29(2):244-256.    doi: 10.12799/jkachn.2018.29.2.244.

The Situation of Life-Sustaining Treatment One Year after Enforcement of the Act on Decisions on Life-Sustaining Treatment for Patients at the End-of-Life in Korea: Data of National Agency for Management of Life-Sustaining Treatment
Ha Yeon Lee, Hwa Jung Kim, Jung Hye Kwon, Sun Kyung Baek, Young-Woong Won, Yu Jung Kim, Su Jin Baik, Hyewon Ryu
Cancer Res Treat. 2021;53(4):897-907.    doi: 10.4143/crt.2021.327.


Reference

2. Yun YH, Kwak M, Park SM, Kim S, Choi JS, Lim HY, Lee CG, Choi YS, Hong YS, Kim SY, Heo DS. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology. 2007. 72:164–171.
Article
3. Keam BS, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, Kim TY, Bang YJ, Heo DS. Aggressiveness of cancer-care near the end-of-life in Korea. Japanese Journal of Clinical On-cology. 2008. 38:381–386.
Article
4. Oh DY, Kim JE, Lee CH, Lim JS, Jung KH, Heo DS, Bang YJ, Kim NK. Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer. 2004. 100:1961–1966.
Article
Full Text Links
  • JKMA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr